周四，生物技术公司Sarepta Therapeutics盘前暴涨34%，公司宣布重组计划，其重磅药品被FDA允许继续销售。
Sarepta周三晚间公布了重大战略重组计划，旨在确保长期财务可持续性。公司计划裁减约500个工作岗位，占其员工总数的36%。这一举措预计每年将节省约4亿美元成本。同时，公司将暂停几个研发项目，包括大部分正在开发的肢带型肌营养不良症基因疗法，以集中资源于核心业务。
此外，美国食品药品监督管理局（FDA）允许Sarepta的杜氏肌营养不良症（DMD）基因疗法Elevidys继续留在市场上，但要求在药品标签上增加黑框警告，提示急性肝损伤和肝衰竭风险。这一决定打消了投资者对该药可能被撤市的担忧。公司首席执行官Doug Ingram表示，这一警告标签似乎已经解决了FDA对将该基因疗法用于仍可行走患儿的担忧，公司仍在与FDA就非行走患者的治疗方案进行沟通。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
